Storia in 7 fonti

Supreme Court Backs Maker of Generic Heart Drug in 'Skinny Label' Case

Court says defendant Amarin Pharma hasn't shown enough harm; remands case to lower court

Raccontata da

washingtonexaminer.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

medpagetoday.comStai leggendo1 mese fa

Supreme Court Backs Maker of Generic Heart Drug in 'Skinny Label' Case

Court says defendant Amarin Pharma hasn't shown enough harm; remands case to lower court

originale

statnews.com

Timeline cronologica

martedì 2 giugno 2026·washingtonexaminer.com
Treatment for millions at stake in 'skinny label' Supreme Court case
The Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. ruling could have a major effect on incentives to invest in research for FDA‑approved medicines.
giovedì 4 giugno 2026·medpagetoday.com
Supreme Court Backs Maker of Generic Heart Drug in 'Skinny Label' Case
Court says defendant Amarin Pharma hasn't shown enough harm; remands case to lower court

1 mese fa

Supreme Court backs generic drugmaker in 'skinny labeling' case

The Supreme Court unanimously ruled that Hikma Pharmaceutical did not infringe patents held by Amarin in a decision with implications for lawsuits over so-called skinny labels.

Leggi questa versione → originale

biopharmadive.com1 mese fa

Generic drugmakers gain key victory in ‘skinny label’ patent case

The Supreme Court ruled that a knockoff version of Amarin’s Vascepa didn’t infringe on patents — a decision with far-reaching implications for the availability of generics.

Leggi questa versione → originale

irishtimes.com1 mese fa

US supreme court backs generic drugmaker over Irish-American firm in patent case

Dublin-based Amarin loses appeal over patent on its cardiovascular drug Vascepa

Leggi questa versione → originale

fiercepharma.com1 mese fa

It's unanimous: SCOTUS agrees with Hikma in 'skinny label' case vs. Amarin

With a resounding unanimous vote, the U.S. | With a resounding unanimous vote, the U.S. Supreme Court has sided with Hikma Pharmaceuticals, ruling that its generic version of Amarin’s fish oil-derived cardiovascular…

Leggi questa versione → originale

washingtonexaminer.com1 mese fa

Treatment for millions at stake in 'skinny label' Supreme Court case

The Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. ruling could have a major effect on incentives to invest in research for FDA‑approved medicines.

Leggi questa versione → originale

giovedì 4 giugno 2026·

endpoints.news

Supreme Court sides with Hikma in 'skinny label' case

The Supreme Court has unanimously sided with Hikma Pharmaceuticals and its “skinny label” version of a prescription-strength fish oil pill in a case that was closely watched by…

giovedì 4 giugno 2026·

irishtimes.com

US supreme court backs generic drugmaker over Irish-American firm in patent case

Dublin-based Amarin loses appeal over patent on its cardiovascular drug Vascepa

giovedì 4 giugno 2026·

statnews.com

Supreme Court backs generic drugmaker in 'skinny labeling' case

The Supreme Court unanimously ruled that Hikma Pharmaceutical did not infringe patents held by Amarin in a decision with implications for lawsuits over so-called skinny labels.

giovedì 4 giugno 2026·

fiercepharma.com

It's unanimous: SCOTUS agrees with Hikma in 'skinny label' case vs. Amarin

With a resounding unanimous vote, the U.S. | With a resounding unanimous vote, the U.S. Supreme Court has sided with Hikma Pharmaceuticals, ruling that its generic version of…

venerdì 5 giugno 2026·

biopharmadive.com

Generic drugmakers gain key victory in ‘skinny label’ patent case

The Supreme Court ruled that a knockoff version of Amarin’s Vascepa didn’t infringe on patents — a decision with far-reaching implications for the availability of generics.